KR20070047757A - 아데노바이러스-매개된 유전자 전달에 의해 종양 괴사인자-관련된 아폽토시스-유도 리간드(ｔｒａｉｌ)를생산하도록 조작된 종양-조직지향성 세포 - Google Patents
아데노바이러스-매개된 유전자 전달에 의해 종양 괴사인자-관련된 아폽토시스-유도 리간드(ｔｒａｉｌ)를생산하도록 조작된 종양-조직지향성 세포 Download PDFInfo
- Publication number
- KR20070047757A KR20070047757A KR1020077000005A KR20077000005A KR20070047757A KR 20070047757 A KR20070047757 A KR 20070047757A KR 1020077000005 A KR1020077000005 A KR 1020077000005A KR 20077000005 A KR20077000005 A KR 20077000005A KR 20070047757 A KR20070047757 A KR 20070047757A
- Authority
- KR
- South Korea
- Prior art keywords
- cells
- trail
- tumor
- tissue
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 54
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 41
- 239000003446 ligand Substances 0.000 title claims abstract description 11
- 230000001404 mediated effect Effects 0.000 title description 10
- 238000001476 gene delivery Methods 0.000 title description 7
- 206010054094 Tumour necrosis Diseases 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract description 266
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims abstract description 100
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims abstract description 100
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 61
- 230000006907 apoptotic process Effects 0.000 claims abstract description 59
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 10
- 230000001939 inductive effect Effects 0.000 claims abstract description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 6
- 102000003390 tumor necrosis factor Human genes 0.000 claims abstract description 6
- 239000013598 vector Substances 0.000 claims abstract description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 15
- 208000026310 Breast neoplasm Diseases 0.000 claims description 15
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 210000005259 peripheral blood Anatomy 0.000 claims description 8
- 239000011886 peripheral blood Substances 0.000 claims description 8
- 210000000130 stem cell Anatomy 0.000 claims description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 claims description 5
- 210000004405 cytokine-induced killer cell Anatomy 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 230000003511 endothelial effect Effects 0.000 claims description 2
- 238000011124 ex vivo culture Methods 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 abstract description 8
- 108700012411 TNFSF10 Proteins 0.000 description 105
- 238000010361 transduction Methods 0.000 description 31
- 230000026683 transduction Effects 0.000 description 31
- 238000003501 co-culture Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 18
- 239000012636 effector Substances 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 210000004881 tumor cell Anatomy 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 11
- 230000030833 cell death Effects 0.000 description 11
- 238000001802 infusion Methods 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000011579 SCID mouse model Methods 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 101000830565 Homo sapiens Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 108010049207 Death Domain Receptors Proteins 0.000 description 6
- 206010028851 Necrosis Diseases 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000017074 necrotic cell death Effects 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 5
- 102000009058 Death Domain Receptors Human genes 0.000 description 5
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 description 5
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 description 5
- 230000001640 apoptogenic effect Effects 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108091007178 TNFRSF10A Proteins 0.000 description 4
- 102100040113 Tumor necrosis factor receptor superfamily member 10A Human genes 0.000 description 4
- 229960004308 acetylcysteine Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 230000006882 induction of apoptosis Effects 0.000 description 4
- 230000001338 necrotic effect Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000034578 Multiple myelomas Diseases 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 3
- 208000037842 advanced-stage tumor Diseases 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000003211 trypan blue cell staining Methods 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 2
- 102000004121 Annexin A5 Human genes 0.000 description 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 2
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 2
- 102100025752 CASP8 and FADD-like apoptosis regulator Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 101150029662 E1 gene Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010040476 FITC-annexin A5 Proteins 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 2
- 101000914211 Homo sapiens CASP8 and FADD-like apoptosis regulator Proteins 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108700019961 Neoplasm Genes Proteins 0.000 description 2
- 102000048850 Neoplasm Genes Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 2
- 108010013985 adhesion receptor Proteins 0.000 description 2
- 102000019997 adhesion receptor Human genes 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 102000044949 human TNFSF10 Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000005918 in vitro anti-tumor Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000004114 suspension culture Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000002476 tumorcidal effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 206010060931 Adenovirus infection Diseases 0.000 description 1
- 108050005848 Annexin A10 Proteins 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 108700003785 Baculoviral IAP Repeat-Containing 3 Proteins 0.000 description 1
- 102100021662 Baculoviral IAP repeat-containing protein 3 Human genes 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 101710082513 C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 description 1
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000014061 Extranodal Extension Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 102100032817 Integrin alpha-5 Human genes 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 108010041014 Integrin alpha5 Proteins 0.000 description 1
- 108010042918 Integrin alpha5beta1 Proteins 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000011589 adenoviridae infectious disease Diseases 0.000 description 1
- -1 adhesion molecules Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 230000005756 apoptotic signaling Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 108700000711 bcl-X Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000001787 dendrite Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 102000048851 human CD44 Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005909 tumor killing Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04017907.9 | 2004-07-29 | ||
| EP04017907A EP1621550A1 (en) | 2004-07-29 | 2004-07-29 | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20070047757A true KR20070047757A (ko) | 2007-05-07 |
Family
ID=34925971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077000005A Ceased KR20070047757A (ko) | 2004-07-29 | 2005-07-21 | 아데노바이러스-매개된 유전자 전달에 의해 종양 괴사인자-관련된 아폽토시스-유도 리간드(ｔｒａｉｌ)를생산하도록 조작된 종양-조직지향성 세포 |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20070264231A1 (enExample) |
| EP (2) | EP1621550A1 (enExample) |
| JP (1) | JP5042826B2 (enExample) |
| KR (1) | KR20070047757A (enExample) |
| CN (1) | CN101076540B (enExample) |
| AT (1) | ATE455847T1 (enExample) |
| AU (1) | AU2005266543B2 (enExample) |
| BR (1) | BRPI0513855A (enExample) |
| CA (1) | CA2571426A1 (enExample) |
| DE (1) | DE602005019050D1 (enExample) |
| DK (1) | DK1771468T3 (enExample) |
| ES (1) | ES2340400T3 (enExample) |
| HR (1) | HRP20100227T1 (enExample) |
| IL (1) | IL180233A (enExample) |
| MX (1) | MX2007001152A (enExample) |
| NO (1) | NO20070956L (enExample) |
| NZ (1) | NZ552223A (enExample) |
| PL (1) | PL1771468T3 (enExample) |
| PT (1) | PT1771468E (enExample) |
| RS (1) | RS51381B (enExample) |
| RU (1) | RU2390558C2 (enExample) |
| SI (1) | SI1771468T1 (enExample) |
| WO (1) | WO2006010558A1 (enExample) |
| ZA (1) | ZA200701231B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0510886A (pt) * | 2004-06-18 | 2007-12-26 | Genentech Inc | método para aumentar a apoptose ou a citotoxicidade em células de mamìferos |
| DE102006020307A1 (de) * | 2006-05-03 | 2007-11-08 | Martin-Luther-Universität Halle-Wittenberg | TNF-related apoptosis-including (TRAIL)stabil transgen exprimierende mesenchymale Stammzellen, Verfahren zu ihrer Herstellung und zu ihrer Verwendung |
| WO2008142862A1 (ja) * | 2007-05-18 | 2008-11-27 | National University Corporation Asahikawa Medical College | 血管内皮前駆細胞の移植による抗がん療法 |
| CN102154213B (zh) * | 2011-01-19 | 2012-07-25 | 郑骏年 | 一种运载荷载细胞因子的双调控溶瘤腺病毒的新型cik细胞 |
| US20140369979A1 (en) * | 2012-02-01 | 2014-12-18 | Postech Academy-Industry Foundation | Vector simultaneously expressing dodecameric trail and hsv-tk suicide genes, and anticancer stem cell therapeutic agent using same |
| CN103288966B (zh) * | 2013-05-17 | 2015-01-21 | 华侨大学 | 一种融合受体及其用于治疗大肠癌的基因药物 |
| RU2552609C1 (ru) * | 2013-10-28 | 2015-06-10 | Федеральное государственное бюджетное учреждение науки Институт молекулярной биотехнологии им. В.А. Энгельгардта Российской академии наук (ИМБ РАН) | Способ получения системы направленной доставки белковых молекул (онколитических белков) в опухолевые ткани на основе активированных лимфоцитов |
| RU2716821C2 (ru) | 2014-10-24 | 2020-03-17 | Калиди Биотерапьютикс, Инк. | Комбинированный иммунотерапевтический подход к лечению рака |
| EP3971284B1 (en) * | 2015-07-29 | 2023-11-08 | ONK Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| US10906951B2 (en) | 2015-07-29 | 2021-02-02 | Onk Therapeutics Limited | Modified natural killer cells and natural killer cell lines having increased cytotoxicity |
| WO2019232631A1 (en) * | 2018-06-06 | 2019-12-12 | Stemcell Technologies Canada Inc. | Kits, compositions and methods for myeloid-derived suppressor cell enrichment |
| US12220465B2 (en) | 2018-11-28 | 2025-02-11 | Washington University | Compositions and methods for targeted treatment and imaging of cancer or tumors |
| WO2020188105A1 (en) | 2019-03-21 | 2020-09-24 | Onk Therapeutics Limited | Modified immune effector cells with increased resistance to cell death |
| EP3712257A1 (en) | 2019-03-21 | 2020-09-23 | ONK Therapeutics Limited | Modified natural killer cells with increased resistance to cell death |
| WO2021209625A1 (en) | 2020-04-17 | 2021-10-21 | Onk Therapeutics Limited | High potency natural killer cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5879672A (en) * | 1994-10-07 | 1999-03-09 | Regeneron Pharmaceuticals, Inc. | Tie-2 ligand 1 |
| AU747602B2 (en) * | 1997-06-04 | 2002-05-16 | Oxford Biomedica (Uk) Limited | Vector |
| JP2004526666A (ja) * | 2000-09-11 | 2004-09-02 | マスク ファウンデーション フォー リサーチ デヴェロップメント | アポトーシスの選択的誘導によって腫瘍を治療するための組成物及び方法 |
| AU2001297677B2 (en) * | 2000-10-24 | 2007-07-05 | Immunex Corporation | Method for dendritic cells based immunotherapy of tumors using combination therapy |
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| JP4493882B2 (ja) * | 2001-06-19 | 2010-06-30 | 株式会社カネカ | 抗原およびこの抗原を識別するモノクローナル抗体 |
-
2004
- 2004-07-29 EP EP04017907A patent/EP1621550A1/en not_active Withdrawn
-
2005
- 2005-07-21 SI SI200530969T patent/SI1771468T1/sl unknown
- 2005-07-21 HR HR20100227T patent/HRP20100227T1/hr unknown
- 2005-07-21 AU AU2005266543A patent/AU2005266543B2/en not_active Ceased
- 2005-07-21 WO PCT/EP2005/007957 patent/WO2006010558A1/en not_active Ceased
- 2005-07-21 DK DK05764208.4T patent/DK1771468T3/da active
- 2005-07-21 RU RU2007107369/13A patent/RU2390558C2/ru not_active IP Right Cessation
- 2005-07-21 AT AT05764208T patent/ATE455847T1/de active
- 2005-07-21 CA CA002571426A patent/CA2571426A1/en not_active Abandoned
- 2005-07-21 KR KR1020077000005A patent/KR20070047757A/ko not_active Ceased
- 2005-07-21 US US11/631,262 patent/US20070264231A1/en not_active Abandoned
- 2005-07-21 PT PT05764208T patent/PT1771468E/pt unknown
- 2005-07-21 JP JP2007522989A patent/JP5042826B2/ja not_active Expired - Fee Related
- 2005-07-21 MX MX2007001152A patent/MX2007001152A/es active IP Right Grant
- 2005-07-21 EP EP05764208A patent/EP1771468B1/en not_active Expired - Lifetime
- 2005-07-21 ES ES05764208T patent/ES2340400T3/es not_active Expired - Lifetime
- 2005-07-21 NZ NZ552223A patent/NZ552223A/en not_active IP Right Cessation
- 2005-07-21 RS RSP-2010/0179A patent/RS51381B/sr unknown
- 2005-07-21 BR BRPI0513855-8A patent/BRPI0513855A/pt not_active IP Right Cessation
- 2005-07-21 ZA ZA200701231A patent/ZA200701231B/xx unknown
- 2005-07-21 CN CN2005800324298A patent/CN101076540B/zh not_active Expired - Fee Related
- 2005-07-21 DE DE602005019050T patent/DE602005019050D1/de not_active Expired - Lifetime
- 2005-07-21 PL PL05764208T patent/PL1771468T3/pl unknown
-
2006
- 2006-12-21 IL IL180233A patent/IL180233A/en not_active IP Right Cessation
-
2007
- 2007-02-20 NO NO20070956A patent/NO20070956L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1771468A1 (en) | 2007-04-11 |
| BRPI0513855A (pt) | 2008-05-20 |
| ZA200701231B (en) | 2008-08-27 |
| RS51381B (sr) | 2011-02-28 |
| AU2005266543B2 (en) | 2012-02-02 |
| MX2007001152A (es) | 2007-04-18 |
| DE602005019050D1 (de) | 2010-03-11 |
| ES2340400T3 (es) | 2010-06-02 |
| IL180233A0 (en) | 2007-07-04 |
| JP5042826B2 (ja) | 2012-10-03 |
| RU2390558C2 (ru) | 2010-05-27 |
| US20070264231A1 (en) | 2007-11-15 |
| DK1771468T3 (da) | 2010-05-25 |
| EP1771468B1 (en) | 2010-01-20 |
| SI1771468T1 (sl) | 2010-07-30 |
| CN101076540B (zh) | 2012-10-24 |
| WO2006010558A1 (en) | 2006-02-02 |
| IL180233A (en) | 2010-12-30 |
| WO2006010558A8 (en) | 2006-08-24 |
| AU2005266543A1 (en) | 2006-02-02 |
| RU2007107369A (ru) | 2008-09-10 |
| JP2008507961A (ja) | 2008-03-21 |
| NO20070956L (no) | 2007-02-20 |
| NZ552223A (en) | 2009-01-31 |
| CA2571426A1 (en) | 2006-02-02 |
| PL1771468T3 (pl) | 2010-07-30 |
| HRP20100227T1 (hr) | 2010-07-31 |
| CN101076540A (zh) | 2007-11-21 |
| ATE455847T1 (de) | 2010-02-15 |
| PT1771468E (pt) | 2010-04-20 |
| EP1621550A1 (en) | 2006-02-01 |
| HK1110874A1 (en) | 2008-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106659742B (zh) | 表达免疫应答刺激细胞因子以吸引和/或激活免疫细胞的基因修饰间充质干细胞 | |
| ES2356154T3 (es) | Citoquinas multifuncionales. | |
| EP1771468B1 (en) | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail) | |
| Wang et al. | Viral vectors expressing interleukin 2 for cancer immunotherapy | |
| US20240180983A1 (en) | Adenovirus encoding il-15 | |
| JP2019509715A (ja) | 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞 | |
| WO2003092579A2 (en) | Compositions and methods for treating cancer with an oncolytic viral agent | |
| CN113416260B (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
| Grisendi et al. | Tumor stroma manipulation by MSC | |
| CN114350616A (zh) | 一种免疫细胞及其制备方法和应用 | |
| CN116059329A (zh) | 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法 | |
| Qian et al. | Gene therapy of cancer: induction of anti-tumor immunity | |
| HK1110874B (en) | Tumor-homing cells engineered to produce tumor necrosis factor-related apoptosis-inducing ligand (trail) | |
| WO2023276395A1 (ja) | キメラサイトカイン受容体 | |
| CN120924501A (zh) | 双基因工程化的间充质干细胞及其应用 | |
| JP2025529961A (ja) | 膜結合型ｉｌ－２１を有する免疫細胞並びにその調製方法及び応用 | |
| WO2023137741A1 (zh) | 一种免疫细胞及其制备方法和应用 | |
| CN119775432A (zh) | 靶向cd56的嵌合信号感受器和用于表达该感受器的细胞 | |
| Havunen | Enhancing adoptive cell therapy of solid tumours with armed oncolytic adenoviruses | |
| Whiteside | The Role of Immune Effector Cells in Immunotherapy of Head and Neck Cancer | |
| HK1233546A1 (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells | |
| HK1233546B (en) | Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20070102 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20100702 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20111116 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20120726 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20111116 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20121026 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20120726 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Appeal identifier: 2012101009152 Request date: 20121026 |
|
| J501 | Disposition of invalidation of trial | ||
| PJ0501 | Disposition of invalidation of trial |
Appeal kind category: Appeal against decision to decline refusal Request date: 20121026 Appeal identifier: 2012101009152 |